Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John O Miners

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
Clinical and Experimental Pharmacology & Physiology|October 9, 2002
Evolution of drug metabolism: hitchhiking the technology bandwagonJohn O Miners
British Journal of Clinical Pharmacology|November 26, 2002
In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudineSam Boase, John O Miners
Methods in Molecular Biology (Clifton, N.J.)|February 14, 2014
Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs)Jin Zhou, John O Miners
British Journal of Clinical Pharmacology|August 8, 2006
Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymesJohn O Miners, Richard O Day
Current Topics in Medicinal Chemistry|September 20, 2013
Generation, validation, and application of a P450 homology modelBenjamin C Lewis, John O Miners
In Silico Pharmacology|December 18, 2014
Molecular dynamics simulations: from structure function relationships to drug discoveryPramod C Nair, John O Miners
Clinical Pharmacology and Therapeutics|December 22, 2025
Reply to "Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data"John O Miners, Thomas M Polasek
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2007
In vitro approaches to investigate mechanism-based inactivation of CYP enzymesThomas M Polasek, John O Miners
Drug Metabolism Reviews|September 29, 2009
Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediatorsKathleen M Knights, John O Miners
Clinical Pharmacology and Therapeutics|May 26, 2025
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et alJohn O Miners, Thomas M Polasek
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
Clinical and Experimental Pharmacology & Physiology|October 9, 2002
Evolution of drug metabolism: hitchhiking the technology bandwagonJohn O Miners
British Journal of Clinical Pharmacology|November 26, 2002
In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudineSam Boase, John O Miners
Methods in Molecular Biology (Clifton, N.J.)|February 14, 2014
Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs)Jin Zhou, John O Miners
British Journal of Clinical Pharmacology|August 8, 2006
Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymesJohn O Miners, Richard O Day
Current Topics in Medicinal Chemistry|September 20, 2013
Generation, validation, and application of a P450 homology modelBenjamin C Lewis, John O Miners
In Silico Pharmacology|December 18, 2014
Molecular dynamics simulations: from structure function relationships to drug discoveryPramod C Nair, John O Miners
Clinical Pharmacology and Therapeutics|December 22, 2025
Reply to "Minor Contribution of UGT1A1 Inhibition to Atazanavir-Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data"John O Miners, Thomas M Polasek
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2007
In vitro approaches to investigate mechanism-based inactivation of CYP enzymesThomas M Polasek, John O Miners
Drug Metabolism Reviews|September 29, 2009
Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediatorsKathleen M Knights, John O Miners
Clinical Pharmacology and Therapeutics|May 26, 2025
Caution with PBPK Modeling Based on the In Vitro Kinetics for Bilirubin Hepatic Uptake and Glucuronidation: Commentary on Dong et alJohn O Miners, Thomas M Polasek
Pageof 14